37.17 0.39 (1.06%) | 02-13 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 52.53 ![]() |
1-year : | 59.44 ![]() |
Resists | First : | 44.98 ![]() |
Second : | 50.89 ![]() |
Pivot price | 40.77 ![]() |
|||
Supports | First : | 35.41 | Second : | 29.46 |
MAs | MA(5) : | 37.45 ![]() |
MA(20) : | 41.1 ![]() |
MA(100) : | 49.83 ![]() |
MA(250) : | 45.85 ![]() |
|
MACD | MACD : | -3.2 ![]() |
Signal : | -3 ![]() |
%K %D | K(14,3) : | 9.6 ![]() |
D(3) : | 5.9 ![]() |
RSI | RSI(14): 35.6 ![]() |
|||
52-week | High : | 71.7 | Low : | 8.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ JANX ] has closed above bottom band by 17.5%. Bollinger Bands are 19.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 37.94 - 38.08 | 38.08 - 38.25 |
Low: | 35.78 - 35.94 | 35.94 - 36.11 |
Close: | 36.88 - 37.13 | 37.13 - 37.42 |
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Thu, 13 Feb 2025
64,072 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Bought by abrdn plc - MarketBeat
Wed, 12 Feb 2025
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $89.90 Average PT from Analysts - MarketBeat
Sun, 09 Feb 2025
Andrew Hollman Meyer Sells 3,334 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock - MarketBeat
Fri, 24 Jan 2025
Janux Therapeutics Appoints Former Amgen Director as Chief Medical Officer - StockTitan
Fri, 24 Jan 2025
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer - Business Wire
Wed, 08 Jan 2025
Janux Therapeutics: mCRPC TAM And Promising JANX007’s Phase 1 Data (NASDAQ:JANX) - Seeking Alpha
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 59 (M) |
Held by Insiders | 3.8e+007 (%) |
Held by Institutions | 7.2 (%) |
Shares Short | 6,410 (K) |
Shares Short P.Month | 0 (K) |
EPS | -8.388e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -8 % |
Return on Assets (ttm) | 164.4 % |
Return on Equity (ttm) | -10 % |
Qtrly Rev. Growth | 1.305e+007 % |
Gross Profit (p.s.) | -23.47 |
Sales Per Share | -3.43 |
EBITDA (p.s.) | -1.32869e+007 |
Qtrly Earnings Growth | -1.2 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -37 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -10.86 |
Price to Cash Flow | 10.43 |
Dividend | 0 |
Forward Dividend | 8.55e+006 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |